Agne Zice: Global ITP Awareness Week – A Personal Note!
Agne Zice, Senior Contract Manager at Low Carbon Contracts Company, shared on LinkedIn:
‘‘Global ITP Awareness Week – A Personal Note
This week (22–28 September) marks Global ITP Awareness Week, and I wanted to take a moment to share something personal.
In April 2021, I was diagnosed with Immune Thrombocytopenia (ITP) – a rare autoimmune condition where the body attacks its own platelets, the cells that help your blood clot. It is unpredictable, invisible to most, and often misunderstood.
I have experienced many ups and downs, including hospital visits, relapses, and moments of deep uncertainty.
Over time, I have learned how to live with it, and this year, I have taken a step further by becoming a trustee of the ITP Support Association.
Most people with ITP appear “fine” on the outside – and that is part of the challenge.
Raising awareness helps improve understanding, research, and support for those affected.
If you would like to learn more, please feel free to reach out to me directly, or visit the ITP Support Association website.
If you are wondering how you can help, there are many ways: donating blood or plasma, supporting and participating in fundraising events, donating via the ITP Support Association website, or simply sharing what you have learned.
Thank you for taking the time to read this.”
Stay informed with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals